Thousands to track omnipod 5 in daily life: will the smart pump deliver on its promise?

NCT ID NCT06144554

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study will follow 2,200 children and adults with type 1 diabetes who are using the Omnipod 5 system, a tubeless insulin pump that automatically adjusts insulin based on continuous glucose monitor readings. Over 12 months, researchers will track how often severe low or high blood sugar events occur and measure changes in A1C and time-in-range. The goal is to see how well the system works in real-world conditions outside of a clinic.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Omnipod 5 System (automated insulin delivery device)
What this could lead to
If successful, this study will confirm that the Omnipod 5 system is safe and effective in everyday life, potentially improving blood sugar control and reducing dangerous highs and lows for people with type 1 diabetes.
What could go wrong
This is an observational registry, not a controlled trial, so results may be influenced by participant behavior or selection bias. It does not test a new treatment, only gathers real-world data on an already-approved device.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Circuit Clinical

    RECRUITING

    Buffalo, New York, 14203, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.